Equities Analysts Issue Forecasts for Biogen FY2025 Earnings

Biogen Inc. (NASDAQ:BIIB) – Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Biogen in a report issued on Thursday, February 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will post earnings per share of $16.13 for the year, down from their prior estimate of $17.04. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%.

Several other research firms also recently weighed in on BIIB. Sanford C. Bernstein assumed coverage on Biogen in a report on Tuesday. They issued a “market perform” rating and a $160.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Biogen in a research note on Thursday. The Goldman Sachs Group dropped their target price on Biogen from $281.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday. Mizuho dropped their target price on Biogen from $251.00 to $207.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. Finally, Bank of America restated a “neutral” rating and issued a $178.00 price target on shares of Biogen in a report on Tuesday, December 10th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $211.96.

Biogen Stock Down 0.8 %

Shares of NASDAQ BIIB opened at $137.33 on Friday. The company has a market capitalization of $20.01 billion, a price-to-earnings ratio of 12.41, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The business has a 50-day moving average of $147.31 and a two-hundred day moving average of $173.80. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently modified their holdings of the company. Inspire Trust Co. N.A. boosted its stake in Biogen by 58.5% during the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock worth $2,113,000 after acquiring an additional 4,025 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Biogen by 0.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock valued at $6,646,000 after purchasing an additional 111 shares during the last quarter. Centre Asset Management LLC increased its holdings in Biogen by 7.7% during the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock worth $7,880,000 after buying an additional 3,698 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Biogen by 1.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock worth $176,982,000 after buying an additional 12,319 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Biogen by 3.2% during the third quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock worth $32,687,000 after buying an additional 5,270 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.